Age as a clinical predictor of relapse after induction therapy in ulcerative colitis

Hepato-Gastroenterology

Volumn 56, Issue 94-95, 2009, Pages 1304-1309

  Jang, Eun Sun ^b   Lee, Dong Ho ^a   Kim, Jaihwan ^b   Yang, Hyo Joon ^b   Lee, Sang Hyub ^a   Park, Young Soo ^a   Hwang, Jin Hyoek ^a   Kim, Jin Wook ^a   Jeong, Sook Hyang ^a   Kim, Nayoung ^a   Jung, Hyun Chae ^b   Song, In Sung ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Age; Predictor; Relapse; Ulcerative colitis

Indexed keywords

MESALAZINE; PREDNISOLONE;

ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; SOUTH KOREA; SYMPTOM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 71949129500     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Irving PM, PR Gibson: Infections and IBD. Nat Clin Pract Gastroenterol Hepatol 2008; 5:18-27.
2. Saussure P, Clerson P, Prost PL, et al: Appendectomy, smoking habits and the risk of developing ulcerative colitis: a case control study in private practice setting. Gastroenterol Clin Biol 2007;31:493-497. (Pubitemid 46877548)
3. Hoie O, Wolters F, L Riis L, et al: Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102:1692-1701. (Pubitemid 47206689)
4. Fujimoto T, Kato J, Nasu J, et al: Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol Hepatol 2007;19:229-235.
5. Kim YM, Myung SJ, Jang WY, et al: Clinical Features at diagnosis and course during the first year of diagnosis in Korean patients with ulcerative colitis. Korean Journal of gastroenterology 2000; 36:9.
6. Niv Y, Abuksis G, Fraser GM: Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 2000;95:693-698. (Pubitemid 30123904)
7. Grimm IS, Friedman LS: Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am 1990;19:361-389.
8. Langholz E, Munkholm P, Nielsen OH, et al: Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991;26:1247-1256.
9. Triantafillidis JK, Emmanouilidis A, Pomonis E, et al: Ulcerative colitis in the elderly: clinical patterns and outcome in 51 Greek patients. J Gastroenterol 2001;36:312-316. (Pubitemid 32515077)
10. Jones HW, Hoare AM: Does ulcerative colitis behave differently in the elderly? Age Ageing 1988;17:410-414.
11. Bitton A, Peppercorn MA, Antonioli DA, et al: Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20. (Pubitemid 32061864)
12. Park SH, Kim YM, Yang SK, et al: Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis 2007;13:278-283. (Pubitemid 46465908)
13. Yang SK, Hong WS, Min YI, et al: Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol 2000;15:1037-1042.
14. Sutherland LR, Martin F, Greer S, et al: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-1898. (Pubitemid 17072238)
15. Lichtiger S, Present DH, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845. (Pubitemid 24188135)
16. Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-86.
17. Powell-Tuck J, Day DW, Buckell NA, et al: Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27:533-537.
18. Baron JH, Connell AM, Lennard-Jones JE: Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89-92.
19. Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-1212.
20. Berner Y, Vigder C, Stern M, et al: [Inflammatory Bowel diseases in the elderly]. Harefuah 2003;142:188-192, 238.
21. Kawanishi H, Kiely J: Immunoregulatory defects in murine aged Peyer's patches. Eur J Immunol 1987;17:1223-1228. (Pubitemid 17148159)
22. Kawanishi H, Kiely J: Immune-related alterations in aged gut-associated lymphoid tissues in mice. Dig Dis Sci 1989;34:175-184. (Pubitemid 19068165)
23. Ebersole JL, Steffen MJ, Pappo J: Secretory immune responses in ageing rats. II. Phenotype distribution of lymphocytes in secretory and lymphoid tissues. Immunology 1988;64:289-294.
24. Sewitch MJ, Abrahamowicz M, Barkun A, et al: Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535-1544. (Pubitemid 36875345)
25. Cerveny P, Bortlik M, Kubena A, et al: Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007;13:1244-1249. (Pubitemid 47597771)
26. Halfvarson J, Jess T, Bodin L, et al: Longitudinal concordance for clinical characteristics in a Swedish-Danish twin population with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1536-1544.
27. Hiwatashi N, Yamazaki H, Kimura M, et al: Clinical course and long-term prognosis of Japanese patients with ulcerative colitis. Gastroenterol Jpn 1991;26:312-318.
28. Stonnington CM, Phillips SF, Melton LJ, et al: Chronic ulcerative colitis: incidence and prevalence in a community. Gut 1987;28:402-409. (Pubitemid 17056873)
29. Rogers BH, Clark LM, Kirsner JB: The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. J Chronic Dis 1971;24:743-773.
30. Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640.
31. Karban A, Eliakim R: Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? World J Gastroenterol 2007;13:2150-2152.
32. Aldhous MC, Drummond HE, Anderson N, et al: Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol 2007;102:589-597. (Pubitemid 46328159)
33. Mahid SS, Minor KS, Soto RE, et al: Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006;81:1462-1471. (Pubitemid 44687433)
34. Fiocchi C: Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol Dietol 2002;48:215-226.
35. Johnson GJ, Cosnes J, Mansfield JC: Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005;21:921-931. (Pubitemid 40529727)
36. Hanauer SB: Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther 2004;20 Suppl 4:97-101.
37. Liu ES, Ye YN, Shin VY, et al: Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis 2003;24:1407-1413.
38. Abraham N, Selby W, Lazarus R, et al: Is smoking an indirect risk factor for the development of ulcerative colitis? An age- and sex-matched case-control study. J Gastroenterol Hepatol 2003;18:139-146. (Pubitemid 36349858)
39. Richardson CE, Morgan JM, Jasani B, et al: Effect of smoking and transdermal nicotine on colonic nicotinic acetylcholine receptors in ulcerative colitis. QJM 2003;96:57-65.
40. Vermeire S, van Assche G, Rutgeerts P: The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:580-586.